drugset / Trial / NCT03695367
Phase 2 Herniorrhaphy Study for Opioid Elimination
Non-randomizedSequentialOpen-labelPrevention
Summary
This is a Phase 2, open-label study in subjects undergoing unilateral open inguinal herniorrhaphy.
Timeline
- Start
- 2018-10-01
- Primary completion
- 2018-11-20
- Completion
- 2018-12-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bupivacaine | Other / unclassified | 300 mg | Other |
| Subject | Ketorolac | Other / unclassified | — | Intravenous |
| Subject | Meloxicam | Small molecule | 9 mg | Other |
| Background | Acetaminophen | Small molecule | 1 g | — |
| Background | Ibuprofen | Small molecule | 600 mg | — |
Indications
No indication recorded.